Verici Dx Plc (LSE:VRCI) has announced notable growth in the uptake of its Tutivia™ test, reporting a 19% increase in ordering clinicians and the addition of nine new transplant centers in Q3. These new partnerships now cover approximately 16% of annual U.S. transplant procedures. The company has also bolstered its commercial team with new hires to support anticipated volume growth in Q4, maintaining its trajectory toward meeting market expectations for the year.
Verici Dx continues to face financial pressures, including ongoing losses and negative cash flows. While technical indicators show some short-term positive signals, valuation concerns persist due to the company’s lack of profitability. Limited earnings call data and corporate events restrict further insights into near-term developments.
About Verici Dx Plc
Verici Dx Plc specializes in advanced clinical diagnostics for organ transplant patients. Its flagship product, the Tutivia™ test, is designed to detect acute transplant rejection, supporting better post-transplant patient management. The company is focused on expanding its footprint across U.S. transplant centers to increase adoption of its diagnostic solutions and improve patient outcomes.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply